National Cancer Survivors Day 2016

whywecelebratencsd

Happy National Cancer Survivors Day!

“There are nearly 14.5 million people living with and beyond cancer in the U.S. today, and more than 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world will gather to recognize these cancer survivors as part of the 29th annual National Cancer Survivors Day®.

National Cancer Survivors Day® is an annual worldwide Celebration of Life that is held on the first Sunday in June. It is the one day each year that people around the world come together to recognize the cancer survivors in their community, to raise awareness of the challenges these survivors face, and, most importantly, to celebrate life.

According to the National Cancer Survivors Day Foundation, administrator for the celebration, “A ‘survivor’ is anyone living with a history of cancer – from the moment of diagnosis through the remainder of life.””

To read the official press release on National Cancer Survivors Day, please click here.

For more information reguarding National Cancer Survivors Day, the National Cancer Survivors Day Foundation, and what you can do to celebrate, please visit www.ncsd.org.

I’m so thankful to be one of the millions of survivors who are able to celebrate this day!

helloiamasurvivor

Tell me how YOU are celebrating today!

FDA Approves Netspot, kit for Gallium Scan

We’ve all been waiting for this very news!!

Here’s the FDA Press release from the FDA website!

FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors

“The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs).

NETs are rare noncancerous (benign) or cancerous (malignant) tumors that develop in the hormone-producing cells of the body’s neuroendocrine system. These cells are found throughout the body in organs, such as the stomach, intestines, pancreas, lungs and other locations. NETs have receptors for somatostatin, a hormone that regulates the endocrine system. Ga 68 dotatate, a positron emitting analogue of somatostatin, works by binding to such receptors.

“Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical,” said Libero Marzella, M.D., Ph.D., director of the Division of Medical Imaging Products in the FDA’s Center for Drug Evaluation and Research. “Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. This information is important for planning the appropriate course of therapy.”

Netspot is supplied as a sterile, single-dose kit for preparation of Ga 68 dotatate injection for intravenous use. The uptake of Ga 68 dotatate reflects the level of somatostatin receptor density in NETs. This uptake can also be seen in a variety of other tumor types or other pathologic conditions, or might occur as a normal variant. The uptake of Ga 68 dotatate may need to be confirmed by histopathology or other assessments.

Three studies established the safety and effectiveness of Netspot. The first compared Ga 68 dotatate images of NETs to images obtained with an approved drug, and then confirmed with computed tomography (CT) and/ or magnetic resonance imaging (MRI); the second evaluated Ga 68 dotatate images using histopathology (the study of tissue changes caused by disease), or clinical follow up as reference standards; and the third evaluated patients with NET recurrence using Ga 68 dotatate images. The results of all three studies confirmed the usefulness of Ga 68 dotatate images in finding the location of the neuroendocrine tumors.

Netspot contributes to overall long-term cumulative radiation exposure, and patients should drink and urinate as often as possible during the first hours following administration to help reduce this risk.  No serious adverse reactions have been identified.

The FDA granted Priority Review and orphan drug designations for Netspot. Priority review status is granted to applications for drugs that, if approved, would be a significant improvement in safety or effectiveness in the treatment of a serious condition. Orphan drug designation provides incentives such as tax credits, user fee waivers, and eligibility for orphan drug exclusivity to assist and encourage the development of drugs for rare diseases.

Netspot is marketed by Advanced Accelerator Applications USA, Inc.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.”

Speaker Spotlight – 2016 National Conference Edition Part 7

drmetz

David C. Metz, MD

Professor of Medicine
Division of Gastroenterology
Hospital of University of Pennsylvania
Philadelphia, PA

pennmedicine

Bio:

Dr Metz is Professor of Medicine and Associate Chief for Clinical Affairs in the Division of Gastroenterology at the University of Pennsylvania in Philadelphia, where he is director of the Acid-Peptic Disease Program and codirector of the GI Physiology Laboratory, the Swallowing Disorders Program and the Neuroendocrine Tumor Program.

He is actively involved in clinical research, patient care, and teaching of students, residents, and fellows. Dr Metz’s clinical research program is particularly active in acid-peptic conditions including hypersecretory states such as Zollinger-Ellison syndrome, Helicobacter pylori infection, nonsteroidal anti-inflammatory drug gastropathy, and gastroesophageal reflux disease. He also has particular expertise in the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. He has been a principal investigator on a number of trials evaluating upper gastrointestinal disease states. He is also active in national gastroenterology societies and was a prior member of the Liason Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative) and the US Food and Drug Administration Gastrointestinal Drugs Advisory Committee. He is vice chair of the North American Neuroendocrine Tumor Society (NANETS)

Dr Metz earned his MBBCh (MD equivalent) from the University of the Witwatersrand in Johannesburg, South Africa. He moved to the United States in 1986 and pursued a residency in internal medicine at Albert Einstein Medical Center in Philadelphia. He completed a fellowship in gastroenterology in Washington, DC, in the combined Georgetown/Veterans Affairs Medical Center/National Institutes of Health (NIH) program. He remained on staff at the NIH for 2 more years as a senior staff fellow, performing basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome specifically.

In 1993, Dr Metz moved to Philadelphia in the role of Assistant Professor in the clinician educator track at the University of Pennsylvania. He was promoted to Associate Professor in 1998 and Full Professor in 2003.

To make an appointment, please contact:

Bonnie Bennett at (215) 349-5562

Perelman Center for Advanced Medicine                                                                        South Pavilion, 4th Floor                                                                                                        3400 Civic Center Boulevard                                                                                 Philadelphia, PA 19104                                                                                                            (800) 789-PENN (7366)

For more information on Dr. David Metz and Penn Medicine at the University of Pennsylvania, please visit their website here.

Dr. Metz at the 2016 National NET Patient Conference:

Topic: The Role of the Gastroenterologist in Diagnosing and Treating NETs

When: Friday, September 23th, 2016 at 10:15AM*

SIGN UP NOW FOR THE 2016 NATIONAL NET PATIENT CONFERENCE in New Orleans, LA from September 22-24th to see Dr. Metz and 19 other experts speak on Neuroendocrine Cancer! 

Registration is $125 per person including

  • Thursday’s Welcome Reception 
  • Breakfast, Lunch, and snacks for both Friday and Saturday
  • And keep your eyes out for some special prizes!

Registration does not include your hotel stay or travel expenses.

For more information and to buy your ticket, click here!!

*Time and Date are subject to change.

To check out some of our other speakers, click here!

Novartis Carcinoid Syndrome Quality of Life Survey

Happy Wednesday!

Today, Novartis Pharmacuticals has released a quality of life survey for NET patients diagnosed with Carcinoid Syndrome.

This survey is two parts and is said to be about 30 minutes long. For taking the first part, which you take immediately, you will be gifted a $20 Amazon gift card in 5-10 business days via email for your time. The second part is to be completed at a later date.

***My experience with the survey only took me about 10-15 minutes at most to complete!***

Here is the information:

QUALITY OF LIFE OF INDIVIDUALS WITH CARCINOID SYNDROME SYMPTOMS

Analysis Group is conducting an online survey study to understand the quality of life of patients with Carcinoid Syndrome and its symptoms. Your participation will advance the knowledge in this field. You will also receive a $20 gift card for Amazon.com for completing each survey, as a compensation for your time.

The Study

Analysis Group is seeking patients with Carcinoid Syndrome to share their experience through a two-part anonymous online survey. The first survey can be completed immediately and you will be invited to take a follow-up survey in 6 months. This study is non-interventional and will not require you to do anything beyond completing online survey questions about your experience with Carcinoid Syndrome symptoms. Analysis Group will email you a $20 gift card for Amazon.com within 5-10 business days of completing each survey.

To Participate

If you answer “Yes” to all the questions below, we welcome your participation in the online survey.

Have you been diagnosed with Carcinoid Syndrome (i.e., pattern of symptoms sometimes seen in people with carcinoid tumors)?

Have you ever experienced any of the following Carcinoid Syndrome symptoms (i.e., symptoms caused by a carcinoid tumor’s secretions of large amounts of the hormone serotonin)?

□ Carcinoid diarrhea

□ Carcinoid heart

□ Cramping

□ Cyanosis

□ Flushing

□ Peripheral edema

□ Wheezing

Are you at least 18 years of age?

Would you be able to spend 30 minutes to complete the survey?

Your participation is voluntary. Your responses expressed during the online survey session will be kept strictly confidential. Please direct any inquiries about the study to qol@analysisgroup.com.

To participate in the study and complete the online survey, please visit the survey link:

https://carcinoidsyndrome.healthresearchstudy.net/…

This research is funded by Novartis. Thank you in advance for your consideration

This is for patients in the USA only.

The Speaker Spotlight – 2016 National Conference Edition Part 6

liu

Eric Liu, MD, FACS Surgeon

RockyMountainCClogo

Bio:

DEGREES & EDUCATION:

Harvard University, Cambridge, MA, AB, 1992-1996, Biochemistry

Columbia University, College of Physicians & Surgeons, New York, NY, MD, 1996-2000

Columbia University, Research Fellowship, Mark Hardy, M.D., Islet Transplantation, 2000-2001

New York-Presbyterian Hospital, New York, NY, Residency in General Surgery, 2001-2004, 2007-2009

National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDK), National Institutes of Health, Senior Clinical Research Fellow, Islet/Autoimmunity Branch, David Harlan, 2004-2007.

Uppsala University, Uppsala, Sweden, Fellowship in Neuroendocrine Oncology, Kjell Oberg, 2009.

Vanderbilt University, Master of Science Clinical Investigation, 2013.

Dr. Liu serves as the Chief Medical Advisor for Healing NET Foundation, a 501(c)(3) dedicated to providing education about neuroendocrine cancers to the medical community, and supporting the best possible care for neuroendocrine patients.

HealingNET (3)

 

BOARD CERTIFICATIONS:

General Surgery

PATIENT CARE PHILOSOPHY:

“My focus is to always treat the patient – not just the disease.  I’ve told people many times that I value quality of life as highly as the quantity of life.  Therefore, I use every resource at my disposal to address the problems.  When treating neuroendocrine cancer, it is absolutely imperative to approach it with a multi-disciplinary approach because it crosses into so many different medical subspecialties.  When we are successful, these people can live good, healthy lives.  I find that giving the patient time and respect are critical to developing a sense of trust, because it is a team effort with the patient in the center.  Our goal at the Rocky Mountain Cancer Center is to build a home for neuroendocrine patients, where they can feel comfortable that everyone has experience in this rare disease and all their questions can be answered.  By having the most advanced expertise, imaging techniques, clinical trials, and treatments available all in one center, we can provide patients with the best hope for a healthy life.”

You can read Dr. Liu’s story on the Healing NET Foundation’s blog, here!

To make an appointment, please call:

Rocky Mountain Cancer Centers: Denver – Midtown                                                    1800 Williams Street                                                                                                               Suite 200                                                                                                                              Denver, CO 80218                                                                                                                     (303) 388-4876

For more information on Dr. Eric Liu and the Rocky Mountain Cancer Centers, please visit their website here.

Dr. Liu at the 2016 National NET Patient Conference:

Topic: Somatostatin Analogs: Which SSA to Choose

When: Saturday, September 24th, 2016 at 2PM*

SIGN UP NOW FOR THE 2016 NATIONAL NET PATIENT CONFERENCE in New Orleans, LA from September 22-24th to see Dr. Liu and 19 other experts speak on Neuroendocrine Cancer! 

Registration is $125 per person including

  • Thursday’s Welcome Reception 
  • Breakfast, Lunch, and snacks for both Friday and Saturday
  • And keep your eyes out for some special prizes!

Registration does not include your hotel stay or travel expenses.

For more information and to buy your ticket, click here!!

*Time and Date are subject to change.

You can also see Dr. Liu speak at the 2016 LungNET Conference on Saturday, June 11th, 2016 in Denver, CO!!

Registration for the 2016 LungNET Conference is $25 per person and includes breakfast, lunch, and snacks!

Registration does not include your hotel stay or travel expenses.

For more information and to buy your ticket to the 2016 LungNET Conference, click here!

Dr. Liu will have extended clinic hours for Wednesday, June 8th through Friday, June 10th. Please book these ASAP as they are also extremely limited and WILL fill up! If you would like to make an appointment, please call (303) 388-4876.

Want the chance to see BOTH amazing conferences? Sign up NOW to get FREE registration for the 2016 LungNET Conference when you register for the 2016 National NET Patient Conference. SEE HOW TO GET FREE REGISTRATION TO THE 2016 LUNGNET CONFERENCE!

The Speaker Spotlight – LungNET Conference 2016

NCAN Bandaid

HealingNET (3)

As many of you know, NCAN in partnership with The Healing NET Foundation have a LungNET specific conference coming up on Saturday, June 11th, 2016 in Denver, CO. I wanted to take this opportunity to introduce you guys to the great speakers that are lined up, including Dr. Kjell Öberg from Uppsala, Sweden!

drramirez

So far, I have introduced you to Dr. Robert Ramirez, if you missed my post on him, be sure to check that out here.

drkornbluth

Craig Kornbluth, M.D.

Bio:

Dr. Craig Kornbluth is a Board Certified Radiologist specializing in Body Imaging.  He completed his undergraduate degree at Yeshiva University in New York, NY and obtained his doctorate from FUHS/The Chicago School of Medicine, in N. Chicago, IL. Dr. Kornbluth completed his Diagnostic Radiology residency at St. Luke/Roosevelt Hospital New York, NY  followed by a Body imaging fellowship at Johns Hopkins Medical Center in Baltimore, MD.

Dr. Kornbluth is a leader in the Denver Medical Community and has been named multiple times on the Top Doctor list in 5280 Magazine.  He has been involved in multiple research projects and lectures across the country on imaging specifically of the Abdomen and pelvis.

Dr. Kornbluth resides with his family in Denver, Colorado.  When Dr. Kornbluth is not working, he spends his time hiking, fly-fishing, biking, golfing and snowboarding in the beautiful Rocky Mountains.

You can find Dr. Kornbluth at Diversified Radiology in Lakewood, CO.

drryan

Margaret Ryan, M.D.

Bio:

Dr. Margaret Ryan has a medical practice in Denver CO. Dr. Ryan specializes in pathology, and has over 8 years of experience in the field of medicine. She graduated from Ohio State University College Of Medicine with her medical degree in 2008. She is affiliated with numerous hospitals in the Denver area including Hca Healthone Llc and more. Dr. Ryan is accepting new patients at her medical office and practice location in Denver, Colorado. She is available for appointments, preventative care, medical care as well as ongoing patient care.

drparker

Richard Parker, M.D.

Bio:

Dr. Richard Parker is board-certified in general, thoracic and cardiovascular surgery. He serves patients at Presbyterian/St. Luke Medical Center and Rose Medical Center. He completed his fellowship in thoracic and cardiovascular surgery at the University of Colorado and his postgraduate fellowship in cardiovascular surgery from Mayo Graduate School of Medicine.

Prior to joining HealthONE, he served as a physician at Colorado Cardiovascular Surgical Associates. Currently, he serves as Chief of Cardiovascular Surgery at Rose Medical Center and Chairman of the Department of Cardiovascular Surgery at Presbyterian/St. Luke Medical Center. He has co-authored several papers and presented research at well-known seminars and conferences.

Dr. Richard Parker is experienced in all aspects of thoracic (heart, lung, esophageal and chest wall) surgery, coronary artery surgery and has been a pioneer in minimal access VATS surgery of the chest. He also has extensive experience in aortic and mitral valve surgery, including the minimal access approach.

For the past 20 years, he has been named one of 5280 magazine’s “Best Doctors”.

For more information on Dr. Parker, you can click here.

drkobitary

Majd Kobitary, M.D., F.C.C.P.

Bio:

Dr. Kobitary is board-certified in Pulmonary Medicine and Critical Care Medicine. He earned his medical degree from Damascus University Medical School. He completed Internal Medicine Residency at St. Francis Hospital in Evanston in Illinois and Pulmonary and Critical Care Fellowship at the University of Wisconsin. He completed an additional fellowship in Interventional Pulmonology from the University of Iowa. He has experience in advanced bronchoscopic procedures such as stenting and laser therapy for tumor removal.

For more information on Dr. Kobitary, click here.

droberg

Kjell Öberg, M.D.

Bio:

Dr. Kjell Öberg is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University. He was the former head of the Department of Endocrine Oncology, University Hospital, and he is a specialist in endocrinology and internal medicine. He founded the Dept. of Endocrine Oncology at Uppsala University Hospital and has 30 years experience in the field of neuroendocrine tumors. Between 1986 and 1992 he was clinical associate director of the Ludwig Institute for Cancer Research. From 1998 to 2002 he was chairman of the Department of Medical Sciences at the Medical Faculty of Uppsala University. Since July 2002 until June 2008 he has been the Dean of the Medical Faculty. He is the chairman of Centre of Excellence of Endocrine Tumors and Vice chairman of the Department of Endocrine Oncology, University Hospital, Uppsala. Currently Adjunct Professor of Surgery at Vanderbilt University, Nashville, US.

Dr. Öberg was one of the founders and coordinator of the European Neuroendocrine Tumor Network (ENET) 1995-2000 and was past chairman of the Nordic Neuroendocrine Tumour Group. He has pioneered the treatment of carcinoid tumor patients with interferon and somatostatin analogues and developed assays for tumor markers such as Chromogranin A and radiological procedures including specialized PET scans.

In 1988 he was the first to describe a genetic deletion in multiple endocrine neoplasia Type 1 (MEN1). Dr Öberg has given many hundreds of presentations at international meetings and published more than 500 papers within his research field, H-factor 64 and more than 12,000 citations. In addition he is the author of numerous chapters on Carcinoid tumors in several international textbooks including William’s Textbook of Endocrinology, Leslie de Groot’s Textbook of Endocrinology, Clinical Endocrinology and Fordtran’s Textbook of Gastroenterology. Dr. Öberg is Editor-in Chief of World Journal of Gastroenterolgy (WJG).

In 1991 Dr. Öberg received the European Interferon Research reward. In 2003 he received the award “Eminent Scientist Year 2003” by the International Research Promotion Council (IRPC) and World Scientist Forum and in 2004 he was awarded the European Gold Medal in Endocrinology from the English Endocrine Society. In November 2006 he received the Harry Boström Award Lecture at Swedish Medical Society. The University Hospital Clinical Research Award in 2011.

Dr. Öberg is a member of the Royal Society of Sciences, member of Swedish Society of Medical Research, Honorary member of Finnish Oncology Society, Finnish Endocrine Society and Honorary member of Spanish Neuroendocrine NET-work. Dr. Öberg is Chairman Elect of ENETS and also a member of NANETS Advisory Board as well as several other national and international research and scientific boards and many scientific journal review boards.

For more on Dr. Öberg, click here.

drcohn

Allen Cohn, M.D.

Bio:

Dr. Allen Cohn is a medical oncologist in Denver, Colorado. He received his medical degree from University of Maryland School of Medicine and has been in practice for more than 20 years. Dr. Cohn’s specialties include Gastrointestinal Cancer, Carcinoid/Neuroendocrine Tumors (NET) and Neurological Oncology.

For more information on Dr. Cohn, click here.

drnutting

Charles Nutting, D.O., F.S.I.R.

Bio:

Dr. Nutting completed his undergraduate education at Loyola University of Chicago and graduated from Chicago College of Osteopathic Medicine in 1992. He did his residency and internship in Diagnostic Radiology at Olympia Fields Hospital and Medical Center in Chicago, IL.  Charles Nutting completed his fellowship in Interventional Radiology at Rush-Presbyterian-St. Luke’s Medical Center in Chicago.  Charles Nutting then practiced at Resurrection Medical Center in Chicago. In addition, Dr. Nutting practiced in Phoenix where he held positions at Phoenix Children’s Hospital, St. Joseph’s Hospital and Medical Center, and served as the Chief of Interventional Radiology at Good Samaritan Regional Medical Center. Dr. Nutting joined Radiology Imaging Associates (RIA) in November of 2004. 

Dr. Nutting is a board-certified, fellowship-trained interventional radiologist specializing in performing minimally invasive image-guided procedures to treat liver cancer and vein disorders.  He has the distinction of being a Fellow of the Society of Interventional Radiology (FSIR). Charles Nutting practices at RIA Endovascular where he does consultations for innovative liver cancer therapies.

Charles Nutting offers leading-edge procedures including chemoembolization, radiofrequency ablation and selective internal radiation therapy (SIRT). When not in the office, he treats endovascular disease, vein disorders and cancer in local and regional hospitals throughout the Rocky Mountain region. He is Chief of Interventional Radiology at Sky Ridge Medical Center.

Dr. Nutting was the first physician in the United States to do liver radioembolization with Sir-Sphere®. He has since performed more than 900 radioembolization procedures, and teaches this SIRT procedure using Y90 internal radiation beads nationwide.

To read more about Dr. Nutting, click here.

liu

Be on the lookout for our last profile on Dr. Eric Liu this Saturday!!

Registration for the 2016 LungNET Conference is $25 per person and includes breakfast, lunch, and snacks!

Registration does not include your hotel stay or travel expenses.

If you missed out on all the basic information about the 2016 LungNET Conference in Denver, CO on Saturday, June 11th, you can find that information here.

Click here to register for the 2016 LungNET Conference!

The Speaker Spotlight – 2016 National Conference Edition Part 5

O'Dorisio

Thomas O’Dorisio, MD

Professor of Medicine, Director of the Neuroendocrine Tumor Clinics Program

UIhosplogo

Bio:

Dr. Thomas O’Dorisio is Professor of Medicine and Director of the Neuroendocrine Tumor Clinics Program in the Holden Comprehensive Cancer Center at the University of Iowa.   Currently 1700 patients with carcinoid and familial/sporadic neuroendocrine tumors in both children and adults are registered via an IRB approved consent form.  With Co-directors Dr. James R. Howe (Endocrine surgeon) and Dr. M. Sue O’Dorisio (Pediatric Oncology), there are seven dedicated multi-disciplinary neuroendocrine tumor clinics weekly that include a neuroendocrine tumor clinic for the Veterans Administration Hospital.  Multi- diagnostic and therapeutic modalities for these patients include the highly sensitive and specific 68-Gallium – DOTATOC PET scan.  We are currently analyzing the safety and efficacy data of 200 subjects who have had this scan.  Therapeutic advances include the registration trial of LU-177 –DOTA-Octretoate therapy, a multi-international institution protocol for progressive midgut carcinoid tumors.  We anticipate the first peptide receptor radio-nuclide therapy (PRRNT) Phase II trial in the United States with Y90-DOTA-(tyr)-Octreotide within the next two months.  We see between 16 and 24 new neuroendocrine patients monthly, and have 900-1200 neuroendocrine patient visits per year. Our Clinical-Clinical Research Center is modeled after the 21 or so European NET Centers of Excellence, dedicated to this rare cancer with a prevalence in the United States of about 110,000 patients and an incidence since 1989 that has risen by 500%.

To see his official University of Iowa Heath Care video profile, please click here.

Education:

BS, Regis College, Denver, Colorado

MS, Anatomy, Creighton University, Omaha, Nebraska

MD, Creighton University, Omaha, Nebraska

Internship, Internal Medicine, Creighton University

Residency, Internal Medicine, The Ohio State University, Columbus, Ohio

Fellowship, Endocrinology, The Ohio State University, Columbus, Ohio

Licensure and Certifications:

Medical License, Iowa Board of Medicine

Certification, The College of American Pathologists (CAP) Ohio

Certification of Accreditation, Department of Health & Human Services Health Care Financing Administration (HCFA) CLIA Laboratory

Certification, American Board of Internal Medicine

To make an appointment as a NEW patient, please call:

The Holden Comprehensive Cancer Center at the University of Iowa                        (319) 356-4200 Option #3, Ask for Molly Becker

University of Iowa Hospitals and Clinics                                                                       200 Hawkins Drive                                                                                                                    Iowa City, IA 52242                                                                                                                 (800) 777-8442

Dr. O’Dorisio at the 2016 National NET Patient Conference:

Topic: PRRT Trials in America: What’s New?

When: Friday, September 23rd, 2016 at 1PM*

Be sure not to miss Dr. O’Dorisio speak! And don’t miss him on our panel answering your questions!!

For more information on Dr. O’Dorisio and the Holden Comprehensive Cancer Center at the University of Iowa, please visit their website here.

SIGN UP NOW FOR THE 2016 NATIONAL NET PATIENT CONFERENCE in New Orleans, LA from September 22-24th to see Dr. O’Dorisio and 19 other experts speak on Neuroendocrine Cancer! 

Registration is $125 per person including

  • Thursday’s Welcome Reception 
  • Breakfast, Lunch, and snacks for both Friday and Saturday
  • And keep your eyes out for some special prizes!

Registration does not include your hotel stay or travel expenses.

For more information and to buy your ticket, click here!!

*Time and Date are subject to change.

The Speaker Spotlight – 2016 National Conference Edition Part 4

Campeau

Richard J. Campeau, MD, FACNM

oschnermedcenterlogo

Bio:

Dr. Richard Campeau is a Clinical Professor of Radiology (Nuclear Medicine) and Internal Medicine (Cardiology) at LSU and Tulane University Health Sciences Centers. Dr. Campeau attended Medical School at LSU School of Medicine. He then completed his internship and residency at Tulane University Health Sciences Centers followed by a fellowship in Nuclear Medicine at Johns Hopkins Hospital in Maryland. Currently, Dr. Campeau is the immediate past President (2007-2008) of the American College of Nuclear Medicine, and is a past President of the Southwest Chapter, Society of Nuclear Medicine. 

Dr. Campeau specializes in I-131 MIBG treatment.

To make an appointment, please contact Pam Ryan, RN:

NOLANETS-New Orleans Louisiana Neuroendocrine Tumor Specialists                  200 West Esplanade, Ste. 200                                                                                        Kenner, LA 70065                                                                                                                    (504) 464-8500                                                                                                                               or toll free: (866) 91-ZEBRA

For more information on the NOLANETS Group and Dr. Richard Campeau, please visit their website here.

Dr. Campeau at the 2016 National NET Patient Conference:

Topic: I-131 MIBG Therapy: Results of our First 100 Cases

When: Friday, September 23rd, 2016 at 1:30PM*

SIGN UP NOW FOR THE 2016 NATIONAL NET PATIENT CONFERENCE in New Orleans, LA from September 22-24th to see Dr. Campeau and 19 other experts speak on Neuroendocrine Cancer! 

Registration is $125 per person including

  • Thursday’s Welcome Reception 
  • Breakfast, Lunch, and snacks for both Friday and Saturday
  • And keep your eyes out for some special prizes!

Registration does not include your hotel stay or travel expenses.

For more information and to buy your ticket, click here!!

*Time and Date are subject to change.

Together Everyone Achieves More

togethereveryoneachievesmoregraphic

Last Wednesday, I posted about the importance of knowing the ins and outs of your disease. Today, I’m expanding a little bit on something I said:

Your care should be treated as a team, not a one person show.

According to Merriam-Webster, team is defined as “a number of persons associated together in work or activity, a group on one side.”

Why is having a multidisciplinary medical team so important?

The most important aspect of treating a NET patient is a care plan that it is tailored to suit the individual. Neuroendocrine cancer care can be complex and for the patient the journey can encompass not only a whole host of emotions, but also a wide range of tests, treatments and health care professionals. Since there are often multiple treatment options available throughout the course of the disease, collaboration is essential among all key health care personnel who are making clinical decisions for individual patients.

In order to deliver the highest quality care to individuals with neuroendocrine tumors, a NET cancer patient should be referred to a center where there is a multidisciplinary team. Ideally, this collaborative group would be led by an expert in the field of NET cancers and include physicians from a wide range of specialties. Though patients may not always see an expert with a multidisciplinary team, it is important to have a NET specialist partnering with other physicians the patient is seeing to ensure the best treatment.

Patients feel more confident in the knowledge that all aspects of their care have been discussed and the best possible treatment plan has been formulated. A well-coordinated and disciplined team are a very critical aspect for care when striving to achieve the best quality of life and the most positive outcomes for NET cancer patients.

In the case of a doctor being unwilling to work with a patient’s NET specialist and the rest of their care team, it is crucial to fire this physician and find one who is willing to work as part of the team.

*Please remember that doctors work ***FOR*** YOU and you do not have to stay with any physician who is not giving you the care that you need or deserve! If they aren’t listening to you or other physicians in your care team, please move on. Sometimes we are lucky enough to like a doctor even though they are not providing the best or right care. Liking a doctor is not a reason to stay with them.*

I hope everyone is having a great week! Until next time…

Tricia Wahmann-Knatz

#StripesforNETCancer Contest Winner!!

And the winner is…

Heather Shea-Martinez!!!

winner

 

Heather, you have won a free registration to NCAN’s 2016 National NET Patient Conference in New Orleans this upcoming September!!

This registration includes all events for the program from Thursday, September 22nd – Saturday, September 24th!

 Including

  • Thursday’s Welcome Reception 
  • Breakfast, Lunch, and snacks for both Friday and Saturday
  • And keep your eyes out for some special prizes!

Registration does not include your hotel stay or travel expenses.

For more information, click here!!

A huge THANK YOU to Heather and her family and friends for their wonderful #StripesforNETCancer photos!!

Thank you to all of our participants and to everyone who has been sending me their photos! Please keep on sending them because I’m working on some projects with them!

If you would like to register for the 2o16 National NET Patient Conference, you can do so here!! Don’t miss out!

Keep your eye out for out next CONTEST coming soon!